

**ACMUI Sub-Committee Final Report on Training & Experience For Authorized Users of Alpha and Beta Emitters under 10 CFR 35.390**

*Submitted on March 16, 2016*

**Nuclear Regulatory Commission (NRC)  
Advisory Committee on the Medical Uses of Isotopes (ACMUI)  
Final Report on Training & Experience for Authorized Users of Alpha and Beta Emitters under 10 CFR 35.390**

**Sub-Committee Members: V. Dilsizian M.D., R. Ennis M.D., S. Langhorst Ph.D., C. Palestro, M.D. (chair), L. Weil, P. Zanzonico, Ph.D.**

**Introduction**

**The Sub-Committee on Training & Experience for Authorized Users was charged with the following tasks:**

- 1.** To determine if the current requirement of 700 hours for training and experience (T&E) for authorized users (AU) of alpha and beta emitters, in 10 CFR 35.390 (Training for use of unsealed byproduct material for which a written directive is required), places hardship on the patient community and to make recommendations for ACMUI action.
- 2.** To establish a recommendation for the total number of hours of T&E for authorized users of such emitters that appropriately balances safety with reasonable patient access to these agents.

**Charge 1:**


**Background:** Radiolabeled antibody treatment of lymphoma with beta emitters was approved by the U. S. FDA approximately 14 years ago. Two agents initially were available: yttrium-90 ibritumomab tiuxetan (Zevalin®) and iodine-131 tositumomab (Bexxar®). Use of both agents,

ACMUI Sub-Committee Final Report on Training & Experience For Authorized Users of Alpha and Beta Emitters under 10 CFR 35.390

Submitted on March 16, 2016

23 which peaked a few years after introduction, has, despite favorable clinical results, steadily  
24 declined since (Figure 1). Bexxar®, in fact, was withdrawn from the market in 2014, because of  
25 a lack of use (fewer than 75 patients treated in 2014).

26 **FIGURE 1 – Number of Zevalin Patients from 2002-2014**



27  
28 (Adapted from Spectrum Pharmaceuticals, ACMUI meeting October 2015)

29 The subcommittee examined the factors that could possibly account for the decrease in  
30 use of these agents.

31 **Lack of knowledge:** According to Dr. Cultrera’s presentation at the Fall 2015 ACMUI meeting,  
32 hematology/oncology fellows are not exposed to these agents during their training so they may  
33 not be aware that these agents are available and consequently do not prescribe them. This is  
34 an educational, not a regulatory issue.

**ACMUI Sub-Committee Final Report on Training & Experience For Authorized Users of Alpha and Beta Emitters under 10 CFR 35.390**

*Submitted on March 16, 2016*

35 **Competition:** Since these agents were introduced about 14 years ago, new, effective, therapies  
36 that do not involve radiation have been developed, and it likely that some of the decrease in  
37 use is related to the availability of these newer agents. This is not unique to radiolabeled  
38 antibodies; this is common to all drugs: as newer, equally or more effective, agents become  
39 available, the use of older agents declines.

40 **Shortage of Authorized Users:** It has been suggested that the infrequent and declining use of  
41 these agents is a direct result of the requirement for 700 hours of T&E to obtain AU status that  
42 went into effect shortly after these agents were introduced. In his letter of 1/25/2016 to the  
43 ACMUI, Dr. Joseph Mace states that to his knowledge, "... no oncologist has been able to  
44 receive AU status under the alternate pathway, since the regulations went into effect..."  
45 Without knowledge of how many oncologists sought AU status prior to the rule change, it is not  
46 possible to assess the significance of this statement. The only way to determine the impact on  
47 AUs that the change in T&E requirements had, would be to have aggregate data on AUs over  
48 time, data, which unfortunately, are not available. These considerations, it would appear,  
49 provide at least prima facie evidence that lack of clinical use of Bexxar® and Zevalin® is not due  
50 to a lack of AUs.

51 The assertion that a shortage of AUs is the cause of the decline in the use of these agents is  
52 undermined by the fact that even at many large medical centers with an abundance of  
53 clinicians and AUs who work closely together, these radiopharmaceuticals are used infrequently

**ACMUI Sub-Committee Final Report on Training & Experience For Authorized Users of Alpha and Beta Emitters under 10 CFR 35.390**

*Submitted on March 16, 2016*

54 (Figure 2). According to his January 2015 letter, Dr. Mace, who receives consultations from  
55 “across the state of Florida” has administered beta emitters, including Zevalin® to more than 40  
56 patients over the past decade, or only about 4 per year.

57 **FIGURE 2 – Zevalin Administrations at Various Institutions**

Institution	Time Period	Total number of Therapies
<b>Memorial Sloan Kettering Cancer Ctr. (NY)</b>	<b>2009-2014</b>	<b>190</b>
<b>University of Maryland (Baltimore)</b>	<b>2002-2014</b>	<b>25</b>
<b>North Shore LIJ Health System (NY)</b>	<b>2005-2014</b>	<b>49</b>
<b>Washington University/Barnes-Jewish Hospital (St. Louis)</b>	<b>2004-2014</b>	<b>55</b>

58

59 (Adapted from Palestro, presented at the ACMUI meeting Oct 2015)

60 **Safety:** The exceptional safety record that has accompanied beta, and more recently alpha  
61 emitting radiopharmaceuticals, is indisputable. Therefore why not reduce the T&E  
62 requirements anyway, regardless of whether or not there is a shortage of AUs? It is important  
63 to note that the excellent safety records achieved with these agents have been attained, in the  
64 majority of cases, by or in conjunction with, AUs who have successfully completed the rigorous  
65 T&E requirements.

**ACMUI Sub-Committee Final Report on Training & Experience For Authorized Users of Alpha and Beta Emitters under 10 CFR 35.390**

*Submitted on March 16, 2016*

66 **SUMMARY:**

67 The ramifications of a change in T&E are potentially significant. In terms of safety, as already  
68 noted, the excellent safety records achieved with these agents have been attained, for the most  
69 part, by or in conjunction with AU's who have successfully completed the rigorous T&E  
70 requirements. Whether or not the safety records would be comparable in the hands of AUs  
71 with considerably less T&E is a matter of conjecture. It has been suggested that 80 hours of  
72 T&E is sufficient for administration of these agents. This is based on the concept that if 80 hours  
73 of T&E is sufficient for radioactive iodine administration which, it has been asserted, is far more  
74 complex and hazardous, then a comparable amount of T&E is sufficient for administration of  
75 alpha & beta emitters. It is important to note that the field of Nuclear Medicine, including  
76 therapy, originated to a great extent in endocrinology, because of the role of radioactive iodine  
77 in the diagnosis and treatment of thyroid disease. Thus endocrinologists have a long history of  
78 familiarity with the use of radioactive materials.

79 Virtually all of the letters in support of a change in T&E support this change for oncologists.  
80 Surely there are other individuals, in other specialties, who are capable of administering these  
81 agents; should they also be included? Finally, should satisfactory completion of T&E allow an  
82 individual to administer all of these agents, or should use be restricted to specific  
83 radiopharmaceuticals as suggested in the February 9<sup>th</sup>, 2016 letter of Hilliard et al. to the  
84 ACMUI?

**ACMUI Sub-Committee Final Report on Training & Experience For Authorized Users of Alpha and Beta Emitters under 10 CFR 35.390**

*Submitted on March 16, 2016*

85 Since it is not possible to conclude that the current T&E requirements are the only, or even the  
86 principal, cause of the decreased use of radiopharmaceuticals like Zevalin® and Bexxar®, and  
87 because of the potential issues raised by the proposed changes in T&E, the subcommittee  
88 recommends against the reduction in the number of hours of T&E required for 10 CFR 35.390  
89 use.

90 **Charge 2:**

91 Establish a recommendation for the total number of hours of T&E for authorized users of alpha  
92 and beta emitters to ensure safety.

93 While, for the reasons stated, the subcommittee at this time opposes the reduction in the  
94 number of hours of T&E, we also recognize the need for a thorough review of the current T&E  
95 requirements. One important reason for this review is that it has been nearly 15 years since the  
96 current requirements were established. Since that time new radiopharmaceuticals have been  
97 introduced and this is a trend that likely will continue. Appropriate T&E requirements for these  
98 agents need to be established.

99 There is another important reason to undertake this review. The educational paradigm has  
100 changed over time. There has been a shift away from prescriptive curricula (i.e. specific number  
101 of classroom hours) to competency-based education. The time has come to reevaluate our  
102 educational approach to T&E, with an emphasis on competency, not just experience.

**ACMUI Sub-Committee Final Report on Training & Experience For Authorized Users of Alpha and Beta Emitters under 10 CFR 35.390**

***Submitted on March 16, 2016***

103 This undertaking is complicated and cannot be completed in weeks or even months. It requires  
104 input from many stakeholders, if it is to be successful. Once established, the T&E requirements  
105 need regular, periodic review, to ensure that they are current.

106 Therefore the subcommittee recommends that the ACMUI establish a standing subcommittee  
107 with the specific charge of periodically reviewing the T&E requirements currently in effect and  
108 making recommendations for changes as warranted.

109 **Endorsement**

110 The report was unanimously approved by the subcommittee on February 24, 2016. However, a  
111 differing opinion with respect to the barriers to access follows:

112 *I support the Subcommittee's assertion that the Training and Experience requirements*  
113 *need to be reviewed and re-evaluated. But I do not agree that the current requirements*  
114 *do not effectively create some barriers to access to care.*

115 *As the Subcommittee Report states, the 700 hour Training and Experience requirement*  
116 *for AUs of alpha and beta emitters is surely not the primary reason why these agents are*  
117 *not frequently used in many major medical centers. There is no shortage of clinicians*  
118 *available and authorized to administer these radiopharmaceuticals, and other factors*  
119 *must contribute to the lack of utilization.*

**ACMUI Sub-Committee Final Report on Training & Experience For Authorized Users of Alpha and Beta Emitters under 10 CFR 35.390**

***Submitted on March 16, 2016***

120 *It is important to acknowledge that this condition may not hold true for the community*  
121 *setting, where NHL patients often receive treatment. NHL patients often live with the*  
122 *disease for many years, and require a varied armamentarium of therapies to address*  
123 *each subsequent recurrence. Many of these patients are elderly, unable to travel, have*  
124 *very limiting medical insurance networks, and may be too frail to tolerate the*  
125 *debilitating side effects of cytotoxic therapies. To assert that all patients have access to*  
126 *RIT is to ignore the logistical barriers that exist for those who are limited to receiving*  
127 *therapy in the rural or community setting. The 700 hour T&E requirement effectively*  
128 *limits AUs to those medical specialties that cover the requirements in residency training.*  
129 *Those specialists may simply not be available in the community setting, creating a real*  
130 *barrier to access for those patients who are unable to seek treatment in a larger medical*  
131 *center.*

132 *Respectfully submitted,*

133 *Laura Weil, ACMUI Patients' Rights Advocate*

134 The report was unanimously approved by the Committee at its public meeting on March 10,  
135 2016.